Vyant Bio, Inc. (VYNT) Financial Statements (2025 and earlier)

Company Profile

Business Address 2370 STATE ROUTE 70 WEST
CHERRY HILL,, NJ 08002
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 8071 - Medical Laboratories (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments20,6082,4443,8801619,5419,502
Cash and cash equivalents20,6082,4443,8801619,5419,502
Restricted cash and investments   350   
Receivables4348701,4437,03810,95811,748
Inventory, net of allowances, customer advances and progress billings475  144144146
Inventory475  144144146
Contract with customer, asset, after allowance for credit loss 70   ✕✕
Disposal group, including discontinued operation802 71   
Asset, held-for-sale, not part of disposal group  156    
Other current assets  6375462,1482,7072,174
Other undisclosed current assets825 888(144)(144)(146)
Total current assets:23,2144,1077,1789,34723,20623,424
Noncurrent Assets
Operating lease, right-of-use asset673  ✕✕✕
Property, plant and equipment1,020 5584,0565,5504,738
Long-term investments and receivables  200    
Long-term investments  200    
Prepaid expense      
Disposal group, including discontinued operation, noncurrent assets 11,508     
Other noncurrent assets  3,7937,16822,00323,46514,272
Other undisclosed noncurrent assets1,221248    
Total noncurrent assets:14,4224,2417,72626,05929,01519,010
TOTAL ASSETS:37,6368,34814,90435,40652,22142,434
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,5042,3332,07213,0678,7158,148
Accounts payable740     
Accrued liabilities764     
Other undisclosed accounts payable and accrued liabilities  2,3332,07213,0678,7158,148
Deferred revenue741,0131,217✕✕✕
Debt157351,53811,10210,4092,109
Derivative instruments and hedges, liabilities    86  
Disposal group, including discontinued operation3,5226591,229   
Deferred revenue and credits✕✕✕✕✕516789
Due to related parties   566535  
Contract with customer, liability✕✕✕✕2,173✕✕
Other undisclosed current liabilities174223350330  
Total current liabilities:5,4314,2636,97227,29319,64011,046
Noncurrent Liabilities
Long-term debt and lease obligation809104117 6243,028
Long-term debt, excluding current maturities     2,654
Capital lease obligations✕✕✕✕ 624374
Finance lease, liability29372107✕✕✕
Liabilities, other than long-term debt4914309325,1922,736
Deferred revenue and credits✕✕✕✕✕789718
Accounts payable and accrued liabilities    305  
Contract with customer, liability✕✕✕✕379✕✕
Due to related parties   252   
Disposal group, including discontinued operation, liabilities 49     
Operating lease, liability5163210✕✕✕
Derivative instruments and hedges, liabilities  11782484,4032,018
Other undisclosed noncurrent liabilities 57  379  
Total noncurrent liabilities:9151055471,3115,8165,764
Total liabilities:6,3464,3687,51928,60425,45616,810
Equity
Equity, attributable to parent31,2903,9807,3856,80226,76525,624
Common stock3  332
Additional paid in capital110,174176,628171,783164,455161,527139,576
Accumulated other comprehensive income (loss)(74)(223)266069 
Accumulated deficit(78,813)(172,425)(164,424)(157,716)(134,834)(113,954)
Total equity:31,2903,9807,3856,80226,76525,624
TOTAL LIABILITIES AND EQUITY:37,6368,34814,90435,40652,22142,434

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues1,1485,7517,30527,47029,12127,049
Cost of revenue  (3,353)(3,701)(18,724)(18,070)(17,104)
Gross profit:1,1482,3983,6048,74611,0519,945
Operating expenses(16,854)(10,581)(9,307)(30,724)(29,673)(26,669)
Operating loss:(15,706)(8,183)(5,703)(21,978)(18,622)(16,724)
Nonoperating income (expense)(2,869)140(1,694)1,605(4,337)921
Investment income, nonoperating  1671783,753(1,901)1,548
Other nonoperating income (expense)5730759(78)(266)(325)
Interest and debt expense(8)(119)(256)(2,120)(78)(454)
Loss from continuing operations before equity method investments, income taxes:(18,583)(8,162)(7,653)(22,493)(23,037)(16,257)
Other undisclosed income from continuing operations before income taxes8     
Loss from continuing operations before income taxes:(18,575)(8,162)(7,653)(22,493)(23,037)(16,257)
Income tax benefit  1,424512 2,079 
Loss from continuing operations:(18,575)(6,738)(7,141)(22,493)(20,958)(16,257)
Loss before gain (loss) on sale of properties:✕(40,859)(6,696)(6,964)(22,493)(20,958)(16,257)
Income (loss) from discontinued operations(22,284)42177   
Net loss:(40,859)(6,696)(6,964)(22,493)(20,958)(16,257)
Other undisclosed net income (loss) attributable to parent  (1,305)2562,12078454
Net loss available to common stockholders, diluted:(40,859)(8,001)(6,708)(20,373)(20,880)(15,803)

Comprehensive Income ($ in thousands)
Annual | Quarterly

12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(40,859)(6,696)(6,964)(22,493)(20,958)(16,257)
Other comprehensive income 74     
Comprehensive loss:(40,785)(6,696)(6,964)(22,493)(20,958)(16,257)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(148)(1,554)2222,111147 
Comprehensive loss, net of tax, attributable to parent:(40,933)(8,250)(6,742)(20,382)(20,811)(16,257)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: